About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 492608, 9 pages
http://dx.doi.org/10.1155/2012/492608
Review Article

Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis

1Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki 7010192, Japan
2Department of Biofunctional Chemistry, Division of Bioscience, Okayama University Graduate School of Natural Science and Technology, 3-1-1 Tsushima-Naka, Okayama 7008530, Japan
3Department of Dermatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 7010192, Japan
4Research Center for Asbestos-Related Diseases, Okayama Rosai Hospital, 1-10-25 Chikko-Midorimachi, Minami-Ku, Okayama 7028055, Japan
5Department of Radiation Oncology, Kawasaki Medical School, 577 Matsushima, Kurashiki 7010192, Japan

Received 30 June 2011; Accepted 3 November 2011

Academic Editor: Vassilis Gorgoulis

Copyright © 2012 Hidenori Matsuzaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Craighead and A. R. Gibbs, Asbestos and Its Diseases, Oxford University Press, New York, NY, USA, 2008.
  2. R. F. Dodson and S. P. Hammar, Asbestos: Risk Assessment, Epidemiology, and Health Effects, CRC Press, Boca Ratton, Fla, USA, 2006.
  3. V. L. Roggli, T. D. Oury, and T. A. Sporn, Springer Science and Business Media, Springer Science and Business Media, New York, NY, USA, 2nd edition, 2004.
  4. K. O’Byrne and V. Rusch, Malignant Pleural Mesothelioma, Oxford University Press, New York, NY, USA, 2006.
  5. A. Baldi, Nova Scientific, Nova Scientific Publishers, New York, NY, USA, 2008.
  6. J. E. Craighead, “Nonthoracic cancers possibly resulting from asbestos exposure,” in Asbestos and Its Diseases, J. E. Craighead and A. R. Gibbs, Eds., pp. 230–252, Oxford University Press, New York, NY, USA, 2008.
  7. R. Rolston and D. Oury, “Other neoplasia,” in Pathology of Asbestos-Associated Diseases, V. L. Roggli, T. D. Oury, and T. A. Sporn, Eds., pp. 217–230, Springer Science and Business Media, New York, NY, USA, 2nd edition, 2004.
  8. J. E. Craighead, Al. Gibbs, and F. Pooley, “Mineralogy of asbestos,” in Asbestos and Its Diseases, J. E. Craighead and A. R. Gibbs, Eds., pp. 23–38, Oxford University Press, New York, NY, USA, 2008.
  9. V. L. Roggli and P. Coin, “Mineralogy of asbestos,” in Pathology of Asbestos-Associated Diseases, V. L. Roggli, T. D. Oury, and T. A. Sporn, Eds., pp. 1–16, Springer Science and Business Media, New York, NY, USA, 2nd edition, 2004.
  10. N. Kurumatani and S. Kumagai, “Mapping the risk of mesothelioma due to neighborhood asbestos exposure,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 6, pp. 624–629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kumagai and N. Kurumatani, “Asbestos fiber concentration in the area surrounding a former asbestos cement plant and excess mesothelioma deaths in residents,” American Journal of Industrial Medicine, vol. 52, no. 10, pp. 790–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Kumagai, N. Kurumatani, T. Tsuda, T. Yorifuji, and E. Suzuki, “Increased risk of lung cancer mortality among residents near an asbestos product manufacturing plant,” International Journal of Occupational and Environmental Health, vol. 16, no. 3, pp. 268–278, 2010. View at Scopus
  13. T. Yamanaka, F. Tanaka, S. Hasegawa et al., “A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma,” Japanese Journal of Clinical Oncology, vol. 39, no. 3, pp. 186–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Hasegawa and F. Tanaka, “Malignant mesothelioma: current status and perspective in Japan and the world,” General Thoracic and Cardiovascular Surgery, vol. 56, no. 7, pp. 317–323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Ohashi, K. Tajima, F. Takahashi et al., “Osteopontin modulates malignant pleural mesothelioma cell functions in vitro,” Anticancer Research, vol. 29, no. 6, pp. 2205–2214, 2009. View at Scopus
  16. C. Tabata, N. Hirayama, R. Tabata et al., “A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma,” European Respiratory Journal, vol. 36, no. 5, pp. 1099–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Yasumitsu, C. Tabata, R. Tabata et al., “Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma,” Journal of Thoracic Oncology, vol. 5, no. 4, pp. 479–483, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Okumura, F. Tanaka, K. Yoneda et al., “Circulating tumor cells in pulmonary venous blood of primary lung cancer patients,” Annals of Thoracic Surgery, vol. 87, no. 6, pp. 1669–1675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Tanaka, K. Yoneda, N. Kondo et al., “Circulating tumor cell as a diagnostic marker in primary lung cancer,” Clinical Cancer Research, vol. 15, no. 22, pp. 6980–6986, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. IARC ,International Agency for Research on Cancer, World Health Organization, “Silica, some silicate, coal dust and para-aramid fibrils,” IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 68, 1997.
  21. N. H. Heintz and B. T. Mossman, “Molecular responses to asbestos: induction of cell proliferation and apoptosis through modulation of redox-dependent cell signaling pathway,” in Asbestos and Its Diseases, J. E. Craighead and A. R. Gibbs, Eds., pp. 120–138, Oxford University Press, New York, NY, USA, 2008.
  22. M. A. L. Atkinson, “Molecular and cellular responses to asbestos exposure,” in Asbestos: Risk Assessment, Epidemiology, and Health Effects, R. F. Dodson and S. P. Hammar, Eds., pp. 39–90, CRC Press, Boca Ratton, Fla, USA, 2006.
  23. A. Caplan, “Rheumatoid disease and pneumoconiosis (Caplan's syndrome),” Proceedings of the Royal Society of Medicine, vol. 52, pp. 1111–1113, 1959. View at Scopus
  24. A. Caplan, R. B. Payne, and J. L. Withey, “A broader concept of Caplan's syndrome related to rheumatoid factors,” Thorax, vol. 17, pp. 205–212, 1962. View at Scopus
  25. J. Schreiber, D. Koschel, J. Kekow, N. Waldburg, A. Goette, and R. Merget, “Rheumatoid pneumoconiosis (Caplan's syndrome),” European Journal of Internal Medicine, vol. 21, no. 3, pp. 168–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. K. M. Reiser and J. A. Last, “Silicosis and fibrogenesis: fact and artifact,” Toxicology, vol. 13, no. 1, pp. 51–72, 1979. View at Scopus
  27. U. F. Haustein and U. Anderegg, “Silica induced scleroderma—Clinical and experimental aspects,” Journal of Rheumatology, vol. 25, no. 10, pp. 1917–1926, 1998. View at Scopus
  28. C. L. Uber and R. A. McReynolds, “Immunotoxicology of silica,” Critical Reviews in Toxicology, vol. 10, no. 4, pp. 303–320, 1982. View at Scopus
  29. K. Steenland and D. F. Goldsmith, “Silica exposure and autoimmune diseases,” American Journal of Industrial Medicine, vol. 28, no. 5, pp. 603–608, 1995. View at Scopus
  30. J. W. Cohen Tervaert, C. A. Stegeman, and C. G. M. Kallenberg, “Silicon exposure and vasculitis,” Current Opinion in Rheumatology, vol. 10, no. 1, pp. 12–17, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Rihova, D. Maixnerova, E. Jancova et al., “Silica and asbestos exposure in ANCA-associated vasculitis with pulmonary involvement,” Renal Failure, vol. 27, no. 5, pp. 605–608, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Bartuňková, D. Pelclová, Z. Fenclová et al., “Exposure to silica and risk of ANCA-associated vasculitis,” American Journal of Industrial Medicine, vol. 49, no. 7, pp. 569–576, 2006. View at Publisher · View at Google Scholar
  33. P. Wu, Y. Miura, F. Hyodoh et al., “Reduced function of CD4+25+ regulatory T cell fraction in silicosis patients,” International Journal of Immunopathology and Pharmacology, vol. 19, no. 2, pp. 357–368, 2006. View at Scopus
  34. H. Hayashi, M. Maeda, S. Murakami et al., “Soluble interleukin-2 receptor as an indicator of immunological disturbance found in silicosis patients,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 1, pp. 53–62, 2009. View at Scopus
  35. H. Hayashi, Y. Miura, M. Maeda et al., “Reductive alteration of the regulatory function of the CD4(+)CD25(+) T cell fraction in silicosis patients,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 4, pp. 1099–1109, 2010.
  36. H. Hayashi, Y. Nishimura, F. Hyodo, et al., “Dysregulation of autoimmunity caused by silica exposure: fas-mediated apoptosis in T lymphocytes derived from silicosis patients,” in Autoimmune Disorders: Symptoms, Diagnosis and Treatment, M. E. Petro, Ed., pp. 293–301, Nova Science Publishers, Hauppauge, NY, USA, 2011.
  37. N. Kumagai, H. Hayashi, M. Maeda, et al., “Immunological effects of silica and related dysregulation of autoimmunity,” in Autoimmune Disorder, C. Mavragani, Ed., vol. 1, InTech Open Access Publisher, Croatia.
  38. T. Otsuki, H. Hayashi, Y. Nishimura et al., “Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients,” International Journal of Immunopathology and Pharmacology, vol. 24, no. 1, supplement, pp. 11S–16S, 2011.
  39. Y. Nishimura, Y. Miura, M. Maeda et al., “Impairment in cytotoxicity and expression of NK cell-activating receptors on human NK cells following exposure to asbestos fibers,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 3, pp. 579–590, 2009. View at Scopus
  40. Y. Nishimura, M. Maeda, N. Kumagai, H. Hayashi, Y. Miura, and T. Otsuki, “Decrease in phosphorylation of ERK following decreased expression of NK cell-activating receptors in human NK cell line exposed to asbestos,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 4, pp. 879–888, 2009. View at Scopus
  41. Y. Nishimura, N. Kumagai, M. Maeda et al., “Suppressive effect of asbestos on cytotoxicity of human NK cells,” International Journal of Immunopathology and Pharmacology, vol. 24, no. 1, supplement, pp. 5S–10S, 2011.
  42. M. Maeda, Y. Nishimura, N. Kumagai et al., “Dysregulation of the immune system caused by silica and asbestos,” Journal of Immunotoxicology, vol. 7, no. 4, pp. 268–278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Dostert, V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp, “Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica,” Science, vol. 320, no. 5876, pp. 674–677, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. S. L. Cassel, S. C. Eisenbarth, S. S. Iyer et al., “The Nalp3 inflammasome is essential for the development of silicosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9035–9040, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Benko, D. J. Philpott, and S. E. Girardin, “The microbial and danger signals that activate Nod-like receptors,” Cytokine, vol. 43, no. 3, pp. 368–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Martinon and J. Tschopp, “Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases,” Cell, vol. 117, no. 5, pp. 561–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Schroder and J. Tschopp, “The Inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. F. Hamilton, S. A. Thakur, and A. Holian, “Silica binding and toxicity in alveolar macrophages,” Free Radical Biology and Medicine, vol. 44, no. 7, pp. 1246–1258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. S. A. Thakur, R. F. Hamilton, and A. Holian, “Role of scavenger receptor A family in lung inflammation from exposure to environmental particles,” Journal of Immunotoxicology, vol. 5, no. 2, pp. 151–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Upadhyay and D. W. Kamp, “Asbestos-induced pulmonary toxicity: role of DNA damage and apoptosis,” Experimental Biology and Medicine, vol. 228, no. 6, pp. 650–659, 2003. View at Scopus
  51. K. Bhattacharya, E. Dopp, P. Kakkar et al., “Biomarkers in risk assessment of asbestos exposure,” Mutation Research, vol. 579, no. 1-2, pp. 6–21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Liu, R. Beri, A. Mueller, and D. W. Kamp, “Molecular mechanisms of asbestos-induced lung epithelial cell apoptosis,” Chemico-Biological Interactions, vol. 188, no. 2, pp. 309–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Philip, D. A. Rowley, and H. Schreiber, “Inflammation as a tumor promoter in cancer induction,” Seminars in Cancer Biology, vol. 14, no. 6, pp. 433–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. S. C. Robinson and L. M. Coussens, “Soluble mediators of inflammation during tumor development,” Advances in Cancer Research, vol. 93, pp. 159–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Federico, F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio, “Chronic inflammation and oxidative stress in human carcinogenesis,” International Journal of Cancer, vol. 121, no. 11, pp. 2381–2386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. WHO website, “Hepatitis C,” http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html#incidence.
  57. WHO website, “New and under-utilized vaccines implementation (NUVI), human papillomavirus (HPV),” http://www.who.int/nuvi/hpv/en/.
  58. Y. Hiraku, S. Kawanishi, T. Ichinose, and M. Murata, “The role of iNOS-mediated DNA damage in infection-and asbestos-induced carcinogenesis,” Annals of the New York Academy of Sciences, vol. 1203, pp. 15–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Toyokuni, “Mechanisms of asbestos-induced carcinogenesis,” Nagoya Journal of Medical Science, vol. 71, no. 1-2, pp. 1–10, 2009. View at Scopus
  60. S. Toyokuni, “Role of iron in carcinogenesis: cancer as a ferrotoxic disease,” Cancer Science, vol. 100, no. 1, pp. 9–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Nagai and S. Toyokuni, “Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials,” Archives of Biochemistry and Biophysics, vol. 502, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Miura, Y. Nishimura, H. Katsuyama et al., “Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells,” Apoptosis, vol. 11, no. 10, pp. 1825–1835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Otsuki, M. Maeda, S. Murakami et al., “Immunological effects of silica and asbestos,” Cellular & Molecular Immunology, vol. 4, no. 4, pp. 261–268, 2007. View at Scopus
  64. M. Maeda, Y. Miura, Y. Nishimura, et al., “Immunological changes in mesothelioma patients and their experimental detection,” Clinical Medicine. Circulatory, Respiratory and Pulmonary, vol. 2, pp. 11–17, 2008.
  65. P. Romagnani, L. Lasagni, F. Annunziato, M. Serio, and S. Romagnani, “CXC chemokines: the regulatory link between inflammation and angiogenesis,” Trends in Immunology, vol. 25, no. 4, pp. 201–209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. U. P. Singh, C. Venkataraman, R. Singh, and J. W. Lillard, “CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication,” Endocrine, Metabolic and Immune Disorders, vol. 7, no. 2, pp. 111–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. A. M. Fulton, “The chemokine receptors CXCR4 and CXCR3 in cancer,” Current Oncology Reports, vol. 11, no. 2, pp. 125–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Lacotte, S. Brun, S. Muller, and H. Dumortier, “CXCR3, inflammation, and autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 1173, pp. 310–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Maeda, Y. Nishimura, H. Hayashi et al., “Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 4, pp. 795–803, 2011. View at Publisher · View at Google Scholar
  70. M. Maeda, Y. Nishimura, H. Hayashi, et al., “Reduction of CXCR3 in an in vitro model of continuous asbestos exposure on a human T-cell line, MT-2,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 3, pp. 470–479, 2011.
  71. S. Murakami, Y. Nishimura, M. Maeda et al., “Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases,” Environmental Health and Preventive Medicine, vol. 14, no. 4, pp. 216–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Motoyama, T. Honma, H. Watanabe, S. Honma, T. Kumanishi, and S. Abe, “Interleukin 6-producing malignant mesothelioma,” Virchows Archiv B, vol. 64, no. 6, pp. 367–372, 1993. View at Scopus
  73. N. Kimura, T. Ogasawara, S. Asonuma, H. Hama, T. Sawai, and T. Toyota, “Granulocyte-colony stimulating factor-and interleukin 6-producing diffuse deciduoid peritoneal mesothelioma,” Modern Pathology, vol. 18, no. 3, pp. 446–450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Eikawa, Y. Ohue, K. Kitaoka et al., “Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6-and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6,” Journal of Immunology, vol. 185, no. 11, pp. 6734–6740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. D. R. Hodge, E. M. Hurt, and W. L. Farrar, “The role of IL-6 and STAT3 in inflammation and cancer,” European Journal of Cancer, vol. 41, no. 16, pp. 2502–2512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. A. M. W. Petersen and B. K. Pedersen, “The role of IL-6 in mediating the anti-inflammatory effects of exercise,” Journal of Physiology and Pharmacology, vol. 57, no. 10, pp. 43–51, 2006. View at Scopus
  77. K. Heikkilä, S. Ebrahim, and D. A. Lawlor, “Systematic review of the association between circulating interleukin-6 (IL-6) and cancer,” European Journal of Cancer, vol. 44, no. 7, pp. 937–945, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Kishimoto, “IL-6: from its discovery to clinical applications,” International Immunology, vol. 22, no. 5, pp. 347–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Yokoyama, H. Osada, H. Murakami et al., “YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation,” Carcinogenesis, vol. 29, no. 11, pp. 2139–2146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Murakami, T. Mizuno, T. Taniguchi et al., “LATS2 is a tumor suppressor gene of malignant mesothelioma,” Cancer Research, vol. 71, no. 3, pp. 873–883, 2011. View at Publisher · View at Google Scholar
  81. Y. Sekido, “Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation,” Pathology International, vol. 61, no. 6, pp. 331–344, 2011. View at Publisher · View at Google Scholar